Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Endometrial Carcinoma

OncoTree code UCEC · 7 articles

Clinical · Molecular biology · Bioinfo & AI

Latent Class Analysis-Derived Classification and Cancer-Specific Death in Endometrial Carcinoma: A Population-Based Cohort Study

Zhao S, Cheng J, Wang H, et al.

JCO precision oncology

This study developed a novel clinical classification for endometrial carcinoma (EC) using latent class analysis (LCA) on a large cohort of 46,772 cases from the SEER program. Five clinically interpretable classes emerged, each associated with distinct risks of cancer-specific mortality (CSM) and TCGA molecular subtypes. Integrating this LCA classification into molecular survival models improved prognostic discrimination. Furthermore, class-specific transcriptomic signatures involving metabolic reprogramming, DNA repair, and immune pathways were identified. The benefits of combined treatments (surgery, radiotherapy, chemotherapy) varied significantly by class, suggesting a more personalized therapeutic approach.

Clinical · Molecular biology · Bioinfo & AI

Molecular subtyping and POLE mutation spectrum in endometrial carcinoma

Uppin M, Thomas DM, Shantappa R, et al.

The Indian journal of medical research

This study characterized the molecular subtypes and the spectrum of POLE gene mutations in a South Indian cohort of endometrial carcinoma patients. Using the ProMisE classification, researchers identified four molecular subgroups: POLE ultra-mutated, MMR-deficient, p53-abnormal, and no specific molecular profile (NSMP). POLE gene sequencing revealed known variants like V411L, as well as several non-hotspot variants, six of which were unique to this cohort and four predicted to be oncogenic. p53-abnormal tumors exhibited a more aggressive phenotype and increased chemotherapy use. The integration of molecular profiling with histopathology is deemed crucial for enhancing endometrial carcinoma classification and prognostic assessment.

Clinical · Molecular biology · Bioinfo & AI

Delineating SWI/SNF gene and subtype expression in cancer

Canfjorden V, Lindén M, Österlund T, et al.

Epigenetics & chromatin

This study investigated the expression of SWI/SNF chromatin remodeling complex genes and its subtypes (cBAF, PBAF, GBAF) across 33 tumor types, utilizing DNA and mRNA data from The Cancer Genome Atlas (approximately 11,000 samples). Researchers found that the expression of certain genes like ACTL6B, DPF1, DPF3, and SMARCD3 varied most among tumor types, with 10 out of 33 tumor types exhibiting distinct expression signatures. While SWI/SNF gene mutations resulted in only minor changes in their own expression, they were linked to downstream regulation of transcriptional programs associated with epigenetic regulation, particularly in colon adenocarcinoma, kidney renal clear cell carcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. These findings could contribute to the development of biomarkers and targeted therapies.

Clinical · Molecular biology

Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis

Chen Y, Lubinga SJ, Ramsey S, et al.

JCO precision oncology

This study assessed the cost-effectiveness of ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) testing to guide initial treatment in stage III/IV primary advanced or recurrent endometrial cancer. Using a decision tree and partitioned survival model, researchers compared lifetime costs and outcomes with and without molecular testing. The findings indicate that ProMisE testing is cost-effective from a payer perspective, with an incremental cost-effectiveness ratio (ICER) of $66,321 USD per quality-adjusted life-year (QALY) gained, well below the $150,000 USD threshold. From a societal perspective, ProMisE testing even resulted in lower costs and higher QALYs. This personalized approach is considered clinically meaningful and of high value.

Clinical · Bioinfo & AI · Molecular biology

Integrating laboratory tests with FIGO staging using machine learning improves long-term prognostic assessment in endometrial cancer

Wang J, Yang Y, Chen Z, et al.

European journal of obstetrics, gynecology, and reproductive biology

This retrospective study developed machine learning models to improve long-term prognostic assessment in endometrial cancer. By integrating routine laboratory tests with FIGO staging, researchers demonstrated a significant enhancement in predicting 5- and 10-year overall and disease-free survival. The K-nearest neighbour model achieved an AUC of 0.876 for 10-year overall survival, outperforming FIGO staging and age alone. This low-cost and accessible approach could optimize prognostic assessment, especially in settings where advanced molecular profiling is limited.

Clinical · Molecular biology

Decoding the 2023 FIGO Staging System in Endometrial Cancer: A Practical, Visually Guided Framework for Molecular Risk-Adapted Care Incorporating the 2025 Risk Group Update

Abacjew-Chmylko A, Razghоnоva Y, Milosz P, et al.

Current oncology reports

The FIGO staging system for endometrial cancer underwent a significant revision in 2023, incorporating refined anatomical criteria and molecular determinants. This update aims to optimize adjuvant treatment selection by maximizing therapeutic benefits while minimizing harm. Molecular subgroups include POLEmut, p53abn, MMRd, and NSMP. The 2025 ESGO-ESTRO-ESP recommendations further enhance this framework by mandating estrogen receptor (ER) assessment within the NSMP category, identifying early-stage disease with an increased risk of recurrence and mortality.

Clinical · Molecular biology

Beyond Histology: A Dual-Cohort Genomic Analysis of 2901 Endometrial Carcinomas Reveals Class-Level Mismatch Repair Effects and Refines Molecular Classification

Sertesen Çamöz E, Karabuğa B, Karaçin C, et al.

Genes

This large genomic analysis of 2901 endometrial carcinomas refines molecular classification by addressing several clinical questions. The study confirms that all four mismatch repair genes (MLH1, MSH2, MSH6, PMS2) confer an equivalently favorable prognosis, validating dMMR status as a class-level prognostic designation. It demonstrates that the exceptional survival benefit associated with POLE-ultramutated tumors is confined to canonical exonuclease-domain hotspot mutations, excluding variants of uncertain significance. Finally, patients with TP53 mutations and high copy-number instability (CNH) are identified as having the most urgent unmet therapeutic need.